title: Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction.
abstract: BACKGROUND
  Serum lipoprotein(a) [Lp(a)] concentration is largely determined by variability at the apolipoprotein(a) gene locus. Most prominent effects relate to polymorphisms in the promoter (a pentanucleotide [PN] repeat) and coding regions (a kringle IV [K4] repeat), the latter of which also affects Lp(a) particle size. The impact of these polymorphisms on cardiovascular risk is poorly understood.
  
  
  RESULTS
  We studied both polymorphisms and Lp(a) levels in 834 registry-based myocardial infarction (MI) patients (38% women) and 1548 population-based controls. Lp(a) concentrations were inversely related with the numbers of K4 and PN repeats. However, the effect of the PN polymorphism was restricted to subjects producing small Lp(a) particles (<or=8 PN 66.1 mg/dL versus >8 PN 8.7 mg/dL; P<0.0001). The odds to present with MI were elevated in individuals producing small Lp(a) particles (<or=22 K4 repeats; OR 1.47 for men and 1.69 for women; P<0.002) and in women with <or=8 PN repeats (OR 1.46, P=0.009). Interestingly, in women, the frequent haplotype with <or=8 PN and <or=22 K4 repeats, which is related to high levels of small Lp(a) particles, resulted in an elevated OR for MI (1.79; P=0.01) independently of Lp(a) serum concentration.
  
  
  CONCLUSIONS
  The K4 and PN repeat polymorphisms largely explain the high variability of serum Lp(a) levels. A haplotype with <or=8 PN and <or=22 K4 repeats is characterized by high concentrations of small Lp(a) particles. Our observation that this haplotype was associated with MI independently of Lp(a) serum levels may suggest that Lp(a) particle size in addition to its concentration may modulate MI risk in women.
authors.affiliation: Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, Germany. stephan.holmer@klinik.uni-regensburg.de
authors.forename: Stephan R
authors.initials: SR
authors.lastname: Holmer
authors.forename: Christian
authors.initials: C
authors.lastname: Hengstenberg
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Kraft
authors.forename: Björn
authors.initials: B
authors.lastname: Mayer
authors.forename: Melanie
authors.initials: M
authors.lastname: Pöll
authors.forename: Susanne
authors.initials: S
authors.lastname: Kürzinger
authors.forename: Marcus
authors.initials: M
authors.lastname: Fischer
authors.forename: Hannelore
authors.initials: H
authors.lastname: Löwel
authors.forename: Gernot
authors.initials: G
authors.lastname: Klein
authors.forename: Günter A J
authors.initials: GA
authors.lastname: Riegger
authors.forename: Heribert
authors.initials: H
authors.lastname: Schunkert
mesh_terms: D001053:Apolipoproteins / Q000235:genetics*; D053241:Apoprotein(a); D005260:Female; D008040:Genetic Linkage; D005838:Genotype; D005858:Germany / Q000453:epidemiology; D006239:Haplotypes; D006801:Humans; D018082:Kringles / Q000235:genetics; D017270:Lipoprotein(a) / Q000097:blood* / Q000235:genetics*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000453:epidemiology / Q000235:genetics*; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D012091:Repetitive Sequences, Nucleic Acid / Q000235:genetics; D012306:Risk
chemical_list: D001053:Apolipoproteins; D017270:Lipoprotein(a); D053241:Apoprotein(a)